As Moderna and Pfizer feud, what is future of access to mRNA technology?
Zain Rizvi of Public Citizen talks about the legal battle between Moderna and Pfizer over patents on mRNA technology. He also addresses the question of access to this vital technology that is used to make COVID-19 vaccines and other medical products
COVID-19 vaccine: Who holds intellectual property rights?
Immunologist Dr. Satyajit Rath and Newsclick’s Prabir Purkayastha talk about the recent debates on the intellectual property rights on vaccines and the possibilities of mass immunization
COVID-19 vaccines: Differences, costs, and challenges
The COVID-19 pandemic saw the fastest development of a vaccine ever, with a number of research collaborations making this feat possible. But many challenges also remain
Vaccine rollout battle: First past the post may win major market share
India’s mass vaccination plans may fail if it does not hold open discussions on its plans with health professionals and the people
UK and Russia announce start of COVID-19 vaccinations from next week
Both Russia’s Sputnik V and the UK’s Pfizer-BioNTech-produced vaccines are reported to be more than 95% effective in their final trials






